Specifically, Shape will utilize its RNAfix RNA editing platform and potentially its AAVid platform for next-generation adeno-associated viruses (AAV) to develop gene therapies. Shape will conduct preclinical research to identify and deliver development candidates discovered by its artificial intelligence-based platforms. Roche will handle development and worldwide commercialization of any products resulting from the collaboration.

Under the deal, Shape will receive an initial payment and be eligible for development, regulatory, and sales milestone payments for a potential aggregate value of over $3 billion. In addition, Shape will be eligible to receive tiered royalties on future product sales resulting from the collaboration.

AI drug development startups raised $2.1B in 1st half of 2021
The market for artificial intelligence (AI) in drug development and discovery has been red-hot in recent years. The potential impact that AI can offer...

Shape to advance RNA tech platform with $112M in new funding
Shape Therapeutics announced it raised $112 million in financing to continue building its growing portfolio of RNA technologies.

FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab...

Shape Therapeutics unveils advanced AAV capsid discovery platform
Shape Therapeutics has unveiled its adeno-associated virus (AAV) discovery platform, AAVid capsid, and results from its first AAV5 variant library in...

New methods could improve AAV quality for viral vector manufacturing
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical...